The 10F.9G2 antibody is specific for mouse CD274, more commonly known as PD-L1 or B7-H1, which acts as a ligand for the T cell co-regulatory receptor PD-1 (CD279). This interaction modulates T cell antigen receptor (TCR) signaling and therefore T cell activation. PD-L1 binding to PD-1 expressed on CD4- CD8- thymocytes participates in the processes of clonal selection, elimination of autoreactive lymphocytes, and development of tolerance. PD-L1 may also bind PD-1 following the receptor-s inducible expression on activated, mature T cells, where it has been proposed to limit T cell activation. PD-L1 is one of a group of -B7- ligands whose interactions with the CD28 receptor family, also including CTLA-4 (CD152), provide a balance of co-stimulatory /co-inhibitory signaling important in T cell activation, tolerance, and autoimmunity.
The 10F.9G2 antibody may be used as a marker for PD-L1 expression on T and B cells, NK cells and on dendritic cells. It is also widely used for analysis of receptor-ligand interaction and function(s) in vitro and in vivo.
Chen A, Ahlen G, Brenndorfer ED, Brass A, Holmstrom F, Chen M, Soderholm J, Milich DR, Frelin L, and Sallberg M. 2011. J. Immunol. 186:5107-5118. (in vivo depletion)
Zhang L, Gajewski TF, and Kline J. 2009. Blood. 114:1545-1552. (in vivo blocking)
Rivas MN, Weatherly K, Hazzan M, Vokaer B, Dremier S, Gaudray F, Goldman M, Salmon I, and Braun MY. 2009. 183:4284-4291. (in vitro blocking)
Brooks DG, Ha S-J, Elsaesser H, Sharpe AH, Freeman GJ, and Oldstone MBA. 2008. Proc. Natl. Acad. Sci. 105:20428-20433. (in vivo blocking)
Koehn BH, Ford ML, Ferrer IR, Borom K, Gangappa S, Kirk AD, and Larsen CP. 2008. J. Immunol. 181:5313-5322. (in vivo blocking)
Chen A, Ahlen G, Brenndorfer ED, Brass A, Holmstrom F, Chen M, Soderholm J, Milich DR, Frelin L, and Sallberg M. 2011. J. Immunol. 186:5107-5118. (in vivo depletion)
Zhang L, Gajewski TF, and Kline J. 2009. Blood. 114:1545-1552. (in vivo blocking)
Rivas MN, Weatherly K, Hazzan M, Vokaer B, Dremier S, Gaudray F, Goldman M, Salmon I, and Braun MY. 2009. 183:4284-4291. (in vitro blocking)
Brooks DG, Ha S-J, Elsaesser H, Sharpe AH, Freeman GJ, and Oldstone MBA. 2008. Proc. Natl. Acad. Sci. 105:20428-20433. (in vivo blocking)
Koehn BH, Ford ML, Ferrer IR, Borom K, Gangappa S, Kirk AD, and Larsen CP. 2008. J. Immunol. 181:5313-5322. (in vivo blocking)
